Uniqsis press releases
FlowSyn continuous flow reactor is making high temperature chemistry available in no time at all
06/2008
The preparation of pharmacologically important 2-amino-pyridines by direct nucleophilic displacement of unactivated 2-chloropyridine requires harsh conditions and is typically low yielding.
This situation can be resolved by the use of metal catalysed cross-coupling conditions, but this necessitates more extensive purification to subsequently remove the metal catalyst.
Alternatively, the direct uncatalysed preparation of 2–morpholinyl-pyridine, for example, may be straightforwardly achieved conversion under continuous throughput conditions by heating a mixture of morpholine and unactivated 2-chloropyridine to 250oC in NMP for only 20 min. 2-Morpholinyl-pyridine is obtained in high yield and excellent purity.
FlowSyn™ is able to perform this chemistry safely and automatically, freeing up the user to concentrate on their next discovery.
FlowSyn continuous flow reactor is making high temperature chemistry available in no time at all
Continuous Flow Synthesis Gets Hotter
05/2008
Raising the reaction temperature achievable with the FlowSyn™ Continuous Flow Reactor has considerably widened the scope of reactions that can be performed, say manufacturers Uniqsis of Cambridge. Reactions can now be carried out at up to 260ºC and pressures up to 1000psi (~70 Bar).
Turning the Tide with Flow Chemistry
04/2008
by Dr Mark Ladlow
The advent of direct microwave heating has become
an established and useful methodology in the synthetic chemists toolbox. An alternative approach, however, utilises continuous processing. ‘Flow chemistry’ has
the potential to deliver advantages on two levels. Firstly, the need to reduce cost is
increasingly attracting the attention of the drug discovery community. In particular, the
adoption of continuous flow processes presents an opportunity to reduce cycle times
and impact the whole of the drug discovery process from early stage R&D to the
eventual successful production of active pharmaceutical ingredients (APIs).
Flow Chemistry Company Moves Ahead
01/2008
Significant developments are reported by Uniqsis, the Cambridge-based joint venture company formed in January 2007 to develop a new concept in flow chemistry, leading to the launch of the FlowSyn™ Continuous Flow Reactor at the end of last year.
Companies unite to deliver product within year!
01/2008
Two Cambridge companies have forged an alliance to overcome the fuzziness of the front end of innovation, resulting in the rapid formation of an entirely new product, from concept to manufacture in less than one year...
Easier Optimisation and Scale-Up with new Flow Reactor
11/2007
Easier scale-up without re-optimisation using a new micro-reactor is described in a new Applications Note from Uniqsis Ltd of Cambridge...
Uniqsis New High Performance Flow Reactor
11/2007
A novel new micro-reactor, now available for the FlowSyn™ reaction system recently launched by Uniqsis Ltd of Cambridge, is claimed to offer major improvements in reproducibility and performance compared with conventional flow reactor designs.
New Continuous Flow Reactor launched
11/2007
Uniqsis Ltd of Cambridge have “Accessible Flow Chemistry” as their maxim, and the new FlowSyn™ Continuous Flow Reactor has clearly been developed with this in mind.
Microreaction System Nears Launch
08/2007
Cambridge UK: Uniqsis Ltd, the Cambridge-based company formed in January 2007 to develop a new concept in microreaction flow chemistry has announced major progress towards launching FlowSyn™ later in the year.
New Company Focuses on Flow Chemistry
05/2007
Two well known Cambridge-based science companies have joined forces to develop a new concept in flow chemistry aimed at bringing this promising synthesis technique within the reach of every laboratory.